Moreover, some classes of glucose-lowering drugs, such as DPP-4 inhibitors, sodium-glucose cotransporter-2 inhibitors (SGLT2i), and GLP1 agonists, have demonstrated significant benefits in reducing major adverse cardiovascular events, heart failure hospitalization, and the progression of CKD [31,32,33,34,35,36,37]. Here, GLP1R is linked to heart failure.